Yanxin Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yanxin Ren has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Qing Yang
Third Affiliated Hospital of Kunming Medical University, Head and Neck Surgery Department, Kunming, Yunnan, China
36 shared publications - Fei Hou
Department of Nuclear Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China
35 shared publications - Fukun Chen
Department of Nuclear Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China. 1
35 shared publications - Haolin Cai
Department of Nuclear Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China
35 shared publications - Hongbo Zhao
Department of Laboratory Animal Science, Kunming Medical University, Kunming, China
35 shared publications - Juan Lv
Department of Nuclear Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China. 1
35 shared publications
Latest Publications
- Open Access
- 25 March 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Study on the mechanism of demethoxycurcumin inhibiting immune escape in nasopharyngeal carcinoma
- 25 March 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Open AccessStudy on the mechanism of demethoxycurcumin inhibiting immune escape in nasopharyngeal carcinoma
- Open Access
- 12 December 2025
- Published by Elsevier in SLAS Technology
- Vol. 36, 100386
Elucidating the role of PBRM1 in NPC via RNA-seq transcriptomic sequencing
- 12 December 2025
- Published by Elsevier in SLAS Technology
- Vol. 36, 100386
Open AccessElucidating the role of PBRM1 in NPC via RNA-seq transcriptomic sequencing
- Open Access
- 9 May 2025
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 20 (1) , 1-9
Tumor-infiltrating CD4+ CD25+ FOXP3+ Treg is associated with plasma EBV DNA and disease progression in nasopharyngeal carcinoma
Regulatory T cells (Tregs) play a significant role in immune evasion within the tumor microenvironment (TME). Nasopharyngeal carcinoma (NPC) is strongly associated with Epstein-Barr virus (EBV) infection. Previous studies have shown that EBV can suppress immune activity. The relationship between plasma EBV DNA levels and Treg infiltration in NPC remains to be elucidated. Some studies have shown that FOXP3, a Treg marker, is a favorable prognostic factor in NPC. However, relying solely on FOXP3 for Treg identification may be unreliable due to its expression in other cell types. Therefore, this study investigated the impact of tumor-infiltrating Tregs identified by CD4, CD25, and FOXP3 triple markers in NPC and the relationship between these Tregs and EBV infection. In this study, 103 NPC patients were included. All tumor slides were stained using multi-immunofluorescence with CD4, CD25, and FOXP3. HALO software was used to analyze whole-slide images. The correlation between two factors was assessed using Spearman analysis. The prognostic value of factors was evaluated using Kaplan-Meier curves and Cox regression. A significant positive correlation was observed between Treg infiltration in tumor tissues and plasma EBV DNA levels (r = 0.3428, p = 0.02). Higher Treg infiltration was significantly associated with poorer progression-free survival (PFS) (p = 0.03) and was an independent risk factor for NPC progression (p = 0.045). CD25 expression was positively correlated with plasma EBV DNA levels (r = 0.3229, p = 0.03). Furthermore, increased Treg infiltration was negatively correlated with peripheral CD8+ T cells (r=-0.3556, p = 0.006). The proportion of peripheral CD8+ T cells in patients with advanced-stage NPC was significantly lower compared to those with early stage (p = 0.02). This study identified tumor-infiltrating CD4+CD25+FOXP3+ Tregs as an independent negative prognostic factor for NPC progression and found higher Treg infiltration positively associated with plasma EBV DNA levels.
- 9 May 2025
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 20 (1) , 1-9
Open AccessTumor-infiltrating CD4+ CD25+ FOXP3+ Treg is associated with plasma EBV DNA and disease progression in nasopharyngeal carcinoma
Regulatory T cells (Tregs) play a significant role in immune evasion within the tumor microenvironment (TME). Nasopharyngeal carcinoma (NPC) is strongly associated with Epstein-Barr virus (EBV) infection. Previous studies have shown that EBV can suppress immune activity. The relationship between plasma EBV DNA levels and Treg infiltration in NPC remains to be elucidated. Some studies have shown that FOXP3, a Treg marker, is a favorable prognostic factor in NPC. However, relying solely on FOXP3 for Treg identification may be unreliable due to its expression in other cell types. Therefore, this study investigated the impact of tumor-infiltrating Tregs identified by CD4, CD25, and FOXP3 triple markers in NPC and the relationship between these Tregs and EBV infection. In this study, 103 NPC patients were included. All tumor slides were stained using multi-immunofluorescence with CD4, CD25, and FOXP3. HALO software was used to analyze whole-slide images. The correlation between two factors was assessed using Spearman analysis. The prognostic value of factors was evaluated using Kaplan-Meier curves and Cox regression. A significant positive correlation was observed between Treg infiltration in tumor tissues and plasma EBV DNA levels (r = 0.3428, p = 0.02). Higher Treg infiltration was significantly associated with poorer progression-free survival (PFS) (p = 0.03) and was an independent risk factor for NPC progression (p = 0.045). CD25 expression was positively correlated with plasma EBV DNA levels (r = 0.3229, p = 0.03). Furthermore, increased Treg infiltration was negatively correlated with peripheral CD8+ T cells (r=-0.3556, p = 0.006). The proportion of peripheral CD8+ T cells in patients with advanced-stage NPC was significantly lower compared to those with early stage (p = 0.02). This study identified tumor-infiltrating CD4+CD25+FOXP3+ Tregs as an independent negative prognostic factor for NPC progression and found higher Treg infiltration positively associated with plasma EBV DNA levels.
- Open Access
- 18 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-14
Viral IL-10 can promote the proliferation, migration and invasion of nasopharyngeal carcinoma cells and inhibit their apoptosis
Purpose Nasopharyngeal carcinoma is a common clinical malignant tumour in the nasopharynx. The secretion of vIL-10 by EB virus can promote the development of nasopharyngeal carcinoma. The purpose of this study was to provide a theoretical basis for potential targets and mechanisms of vIL-10 in nasopharyngeal carcinoma. Methods A total of 100 ng/mL vIL-10 was applied to the nasopharyngeal carcinoma CNE-2 cell line for 48 h, and then whole transcriptome sequencing analysis was performed to identify potential targets and signalling pathways of vIL-10 in nasopharyngeal carcinoma. The effects of vIL-10 on the proliferation, migration, invasion and apoptosis of human nasopharyngeal carcinoma cells were determined by ELISA, Ki67 immunofluorescence, colony formation, transwell migration/invasion, Hoechst 33,258 staining, flow cytometry and other experiments, and the potential effects of vIL-10 on nasopharyngeal carcinoma cells were verified at the cellular level. Western blotting was performed to measure the changes in key factors of the JAK1-STAT3 signalling pathway in nasopharyngeal carcinoma cells after vIL-10 treatment. Results The whole transcriptome gene sequencing results showed that vIL-10 could effectively activate the JAK-STAT signalling pathway and upregulate the expression of JAK1 and STAT3. Moreover, vIL-10 inhibited the apoptosis of nasopharyngeal carcinoma cells, enhanced their migration and invasion capabilities, and further promoted the proliferation of nasopharyngeal carcinoma cells. Conclusion vIL-10 regulates the JAK1-STAT3 signalling pathway, promotes the proliferation of NPC cells, enhances their migration and invasion capabilities, inhibits tumour cell apoptosis, and participates in the progression of nasopharyngeal carcinoma.
- 18 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-14
Open AccessViral IL-10 can promote the proliferation, migration and invasion of nasopharyngeal carcinoma cells and inhibit their apoptosis
Purpose Nasopharyngeal carcinoma is a common clinical malignant tumour in the nasopharynx. The secretion of vIL-10 by EB virus can promote the development of nasopharyngeal carcinoma. The purpose of this study was to provide a theoretical basis for potential targets and mechanisms of vIL-10 in nasopharyngeal carcinoma. Methods A total of 100 ng/mL vIL-10 was applied to the nasopharyngeal carcinoma CNE-2 cell line for 48 h, and then whole transcriptome sequencing analysis was performed to identify potential targets and signalling pathways of vIL-10 in nasopharyngeal carcinoma. The effects of vIL-10 on the proliferation, migration, invasion and apoptosis of human nasopharyngeal carcinoma cells were determined by ELISA, Ki67 immunofluorescence, colony formation, transwell migration/invasion, Hoechst 33,258 staining, flow cytometry and other experiments, and the potential effects of vIL-10 on nasopharyngeal carcinoma cells were verified at the cellular level. Western blotting was performed to measure the changes in key factors of the JAK1-STAT3 signalling pathway in nasopharyngeal carcinoma cells after vIL-10 treatment. Results The whole transcriptome gene sequencing results showed that vIL-10 could effectively activate the JAK-STAT signalling pathway and upregulate the expression of JAK1 and STAT3. Moreover, vIL-10 inhibited the apoptosis of nasopharyngeal carcinoma cells, enhanced their migration and invasion capabilities, and further promoted the proliferation of nasopharyngeal carcinoma cells. Conclusion vIL-10 regulates the JAK1-STAT3 signalling pathway, promotes the proliferation of NPC cells, enhances their migration and invasion capabilities, inhibits tumour cell apoptosis, and participates in the progression of nasopharyngeal carcinoma.
- Open Access
- 27 November 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1475176
Long-term outcomes of induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
Background: Nasopharyngeal carcinoma (NPC) is a prevalent form of head and neck cancer, particularly in specific regions with a higher incidence. The optimal treatment strategy for locally advanced NPC (stage III and IVA, LA-NPC) involves various combinations of induction chemotherapy (IC), concurrent chemoradiotherapy (CCRT), and adjuvant chemotherapy (AC), each with distinct advantages. This one institutional study aims to retrospectively analysis the efficacy and clinical outcomes of IC with CCRT (IC+CCRT), CCRT with AC (CCRT+AC), and the comprehensive approach of IC followed by CCRT and subsequently AC (IC+CCRT+AC) in the management of LA-NPC.Materials and methods: A total of 352 LA-NPC patients were included: 173 accepted IC+CCRT, 60 received CCRT+AC, and 119 underwent IC+CCRT+AC. The primary endpoints including overall survival (OS) and progression-free survival (PFS), were assessed using the Kaplan-Meier method and log-rank test.Results: The median follow-up was 61.2 months (1-216 months). There was no significant difference in 5-year OS and PFS between IC group and no IC group, extending the observation time to 90 months, the OS and PFS were significantly better in IC group than no IC group (OS: 76% vs. 70%,P<0.05; PFS: 76% vs. 71%, P<0.05). Patients with 1, 2, or 3 cycles of IC had higher 5-year OS and PFS than those with more than 3 cycles (1-4 cycles IC OS: 89% vs. 87% vs. 88% vs. 79%, P<0.05; 1-4 cycles IC PFS: 87% vs. 85% vs. 85% vs. 70%, P<0.05). NP regimen demonstrated higher OS and PFS than TP, PF, and TPF regimens (OS: 95% vs. 82% vs. 85% vs. 71%, P<0.05; PFS: 93% vs. 83% vs. 81% vs. 80%, P<0.05). The 5-year OS and PFS were significantly better in AC group than no AC group (OS: 82% vs. 72%, P<0.05; PFS: 81% vs. 69%, P<0.05). In the AC group, there was no differential effect of chemotherapy cycles and chemotherapy regimens on patients’ OS and PFS. In the ThNh group, patients receiving IC+CCRT+AC had higher OS and PFS compared to those receiving IC+CCRT, with no significant difference in the rest (OS: 85% VS 66% P<0.05; PFS: 78% VS 62%, P<0.05).Conclusion: CCRT combined with IC or AC could benefit LA-NPC patients. The IC+CCRT +AC regimen was most beneficial for NPC patients with later T and N stages.
- 27 November 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1475176
Open AccessLong-term outcomes of induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
Background: Nasopharyngeal carcinoma (NPC) is a prevalent form of head and neck cancer, particularly in specific regions with a higher incidence. The optimal treatment strategy for locally advanced NPC (stage III and IVA, LA-NPC) involves various combinations of induction chemotherapy (IC), concurrent chemoradiotherapy (CCRT), and adjuvant chemotherapy (AC), each with distinct advantages. This one institutional study aims to retrospectively analysis the efficacy and clinical outcomes of IC with CCRT (IC+CCRT), CCRT with AC (CCRT+AC), and the comprehensive approach of IC followed by CCRT and subsequently AC (IC+CCRT+AC) in the management of LA-NPC.Materials and methods: A total of 352 LA-NPC patients were included: 173 accepted IC+CCRT, 60 received CCRT+AC, and 119 underwent IC+CCRT+AC. The primary endpoints including overall survival (OS) and progression-free survival (PFS), were assessed using the Kaplan-Meier method and log-rank test.Results: The median follow-up was 61.2 months (1-216 months). There was no significant difference in 5-year OS and PFS between IC group and no IC group, extending the observation time to 90 months, the OS and PFS were significantly better in IC group than no IC group (OS: 76% vs. 70%,P<0.05; PFS: 76% vs. 71%, P<0.05). Patients with 1, 2, or 3 cycles of IC had higher 5-year OS and PFS than those with more than 3 cycles (1-4 cycles IC OS: 89% vs. 87% vs. 88% vs. 79%, P<0.05; 1-4 cycles IC PFS: 87% vs. 85% vs. 85% vs. 70%, P<0.05). NP regimen demonstrated higher OS and PFS than TP, PF, and TPF regimens (OS: 95% vs. 82% vs. 85% vs. 71%, P<0.05; PFS: 93% vs. 83% vs. 81% vs. 80%, P<0.05). The 5-year OS and PFS were significantly better in AC group than no AC group (OS: 82% vs. 72%, P<0.05; PFS: 81% vs. 69%, P<0.05). In the AC group, there was no differential effect of chemotherapy cycles and chemotherapy regimens on patients’ OS and PFS. In the ThNh group, patients receiving IC+CCRT+AC had higher OS and PFS compared to those receiving IC+CCRT, with no significant difference in the rest (OS: 85% VS 66% P<0.05; PFS: 78% VS 62%, P<0.05).Conclusion: CCRT combined with IC or AC could benefit LA-NPC patients. The IC+CCRT +AC regimen was most beneficial for NPC patients with later T and N stages.
- Open Access
- 19 November 2024
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 91 (2) , 101534
Impact of smoking and alcohol drinking on the prognosis of 721 nasopharyngeal carcinoma
- 19 November 2024
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 91 (2) , 101534
Open AccessImpact of smoking and alcohol drinking on the prognosis of 721 nasopharyngeal carcinoma
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S5. Protein expression categorized into 4 levels.
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S5. Protein expression categorized into 4 levels.
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S2. Relevant clinical information of 44 LMDTC and 25 NMDTC patients used for 4D Label-free proteomic analysis, PRM, and IHC dual validation
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S2. Relevant clinical information of 44 LMDTC and 25 NMDTC patients used for 4D Label-free proteomic analysis, PRM, and IHC dual validation
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S6. Proteins with degree>40 in the PPI network
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S6. Proteins with degree>40 in the PPI network
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S4. WGCNA analysis of the proteomics data.
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S4. WGCNA analysis of the proteomics data.